Posted by Michael Wonder on 29 Apr 2017
FDA approves Radius Health's Tymlos (abaloparatide), a bone building agent for the treatment of postmenopausal women with osteoporosis at high risk for fracture
28 April 2017 - Approval Based on Results at 18 months from the Landmark ACTIVE Trial and the first six months of ACTIVExtend Trial.
Radius Health today announced that the US FDA has approved Tymlos (abaloparatide) injection for the treatment of post-menopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
In post-menopausal women with osteoporosis, Tymlos reduces the risk of vertebral and non-vertebral fractures.
